Related Experiment Videos
Does PTCA in acute myocardial infarction affect mortality and reinfarction rates? A quantitative overview
1Department of Epidemiology, Harvard School of Public Health, Boston, Mass.
Insights
Primary percutaneous transluminal coronary angioplasty (PTCA) after acute myocardial infarction (AMI) may reduce short-term mortality and reinfarction. However, routine PTCA after thrombolysis shows no early benefit, though it may reduce later mortality in select cases.
Area of Science:
- Cardiology
- Interventional Cardiology
Background:
- Percutaneous transluminal coronary angioplasty (PTCA) is frequently used post-acute myocardial infarction (AMI).
- Its impact on mortality and reinfarction rates remains uncertain due to inconsistent trial results.
Purpose of the Study:
- To systematically evaluate the effect of PTCA on mortality and reinfarction in patients with AMI.
- To analyze different PTCA strategies, including primary PTCA and PTCA following thrombolysis.
Main Methods:
- A meta-analysis of 7 trials on primary PTCA and 16 trials on PTCA after thrombolysis was conducted.
- A total of 8496 patients were included, examining various PTCA timing and strategy protocols.
- Data were analyzed to assess short-term and long-term outcomes.
Main Results:
- Primary PTCA significantly reduced short-term mortality (OR 0.56) and the combined endpoint of mortality/reinfarction (OR 0.53).
- PTCA after thrombolysis showed no significant early mortality difference compared to thrombolysis alone.
- A reduction in mortality between 6 and 52 weeks was observed in trials using routine PTCA post-thrombolysis (OR 0.58).
Conclusions:
- Primary PTCA appears more beneficial than thrombolytic therapy for AMI, but requires confirmation in larger studies.
- Routine PTCA addition to thrombolysis does not consistently improve outcomes over conservative, indicated-only PTCA.
- Specific strategies like rescue PTCA for high-risk patients may offer benefits.
Background:
Percutaneous transluminal coronary angioplasty (PTCA) is often performed after acute myocardial infarction (AMI) either as an adjuvant to thrombolytic therapy or instead of thrombolysis. The effect of PTCA in AMI on mortality and reinfarction has remained unclear, with the available randomized trials indicating inconsistent results.
Methods And Results:
A systematic overview (meta-analysis) of the randomized trials was conducted to assess the effect of PTCA in AMI on mortality and reinfarction rates. Data from 7 trials in which primary PTCA was evaluated and 16 trials in which PTCA after thrombolysis was studied were included in this overview, comprising a total of 8496 patient. The trials represented different approaches to the timing of PTCA after AMI. The trials of PTCA after thrombolytic therapy were also categorized according to the different protocols with respect to the routine or elective character of PTCA in the invasive group. A reduction in short-term (6 week) mortality (odds ratio, 0.56; 95% CI, 0.33, 0.94) and in the combined outcome of short-term mortality and nonfatal reinfarction (odds ratio, 0.53; 95% CI, 0.35, 0.80) was observed in the trials comparing primary PTCA with thrombolytic therapy. In contrast, in trials in which an approach of thrombolysis and PTCA was compared with thrombolytic therapy alone, there was no important difference in early mortality, with an apparent reduction in mortality between 6 and 52 weeks. The lower mortality between 6 and 52 weeks among 6-week survivors seemed to be restricted to the subgroup of trials in which PTCA was used as a routine strategy (odds ratio, 0.58; 95% CI, 0.39, 0.87).
Conclusions:
Although the analyses of the various categories of trials suggest that primary PTCA may be more beneficial than thrombolytic therapy in AMI, these data should be interpreted cautiously unless confirmed by larger studies. In contrast, the addition of various other strategies of PTCA to thrombolytic therapy does not convincingly indicate a clinically different outcome than if a more conservative strategy is followed, in which PTCA is used only if clinically indicated. Some specific strategies, however, such as rescue PTCA in high-risk patients with occluded arteries, may be of benefit.